Discover the new educational ERN Rare-Liver webinar series launched in November 2020.
In this fifth webinar which took place on 9 March 2021, Prof Calderaro, Prof Paradis and Dr Forner discuss about the cellular origin and the molecular alterations, the challenge for pathologist that represents a combined hepatocellular-cholangiocarcinoma, as well as the therapeutic perspectives for patients.
- General practitioners
- Health care professionals
1. Cell of Origin and Molecular Alterations
2. Combined Hepatocellular Cholangiocarcinoma: A Challenge for the Pathologist
3. Therapeutic Perspectives
|Alejandro Forner, MD is board certified in gastroenterology and hepatology. Dr Forner’s clinical activity is focused on the care of patients with cirrhosis and hepatocellular carcinoma (HCC). His investigational fields are the early diagnosis of HCC, the treatment of early HCC and the diagnosis and management of intrahepatic cholangiocarcinoma.|
|Valérie Paradis, MD PhD and Professor in Pathology, is the chairman of Pathology department (Beaujon Hospital) and leader of the INSERM team ‘From inflammation to neoplasia in digestive diseases’ (INSERM UMR 1149 Paris). Fields of interest and research include pathological and molecular aspects of liver tumorigenesis. Her team has developed original in situ proteomic approach for identification of tissue biomarkers, and ex vivo culture model of human tumor slices for evaluation of therapeutic molecules.|
|Julien Calderaro, MD PhD, is Professor of Pathology in the Department of Pathology of Henri Mondor University Hospital in Créteil, France. He is specialised in the field of liver diseases and tumors diagnosis. His main research areas are the relationships between the tumor phenotype and genotype, immune microenvironment and the application of artificial intelligence approaches on histological slides for the development of innovative biomarkers.|